study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
MET-OMEGA-PREDIAB_01,2012,randomized controlled trial,SMD,-0.273,-0.413,-0.133,65,63,some concerns,10.1234/omega-3-met-omega-prediab-01,metabolic_journal,prediabetes,Adults with prediabetes concerns,Transient headache,11
MET-OMEGA-PREDIAB_02,2013,randomized controlled trial,SMD,-0.3502,-0.5362,-0.1642,80,66,mixed,10.1234/omega-3-met-omega-prediab-02,metabolic_journal,prediabetes,Adults with prediabetes concerns,Mild GI discomfort,8
MET-OMEGA-PREDIAB_03,2014,randomized controlled trial,SMD,-0.3634,-0.5313,-0.1955,61,69,some concerns,10.1234/omega-3-met-omega-prediab-03,metabolic_journal,prediabetes,Adults with prediabetes concerns,None reported,8
